美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.69

-0.4365-1.24%

盤後：34.720.0307+0.09%16:15 EDT

成交量：2.55萬

成交額：88.51萬

市值：9,643.63萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.14

換手率：0.92%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

創新藥企赴港IPO提速小分子創新藥成主力賽道

经济参考报

華泰證券：港股基本面與貼現率賽跑首選紅利及創新藥

B7-H3靶點ADC全球率先突破世界肺癌大會迎來中國時刻

中国新闻网

WCLC大會開幕！一文搞懂創新藥臨床指標

創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線

情緒冰點，A股單周成交額創年內新低！有色領跌，創新藥不振！關注華寶基金創業板人工智能ETF

從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局

阿斯利康：SERENA-4臨床試驗未達到主要終點。

創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用

重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線

放量普跌！有色突遭重挫，創新藥跌跌不休！光模塊逆市獨漲，高「光」創業板人工智能ETF（159363）V型拉升

興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗

興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類

昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數

一品紅痛風創新藥Ⅲ期臨床達到主要終點大中華區銷售峯值預計達19.5億元

港股異動 | 創新藥概念股持續調整海外利率預期反覆 2026國談收官進入結果等待期

涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

華東醫藥：創新藥HDM2005入選國家科技重大專項

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6893,"timestamp":1789761600000,"preClose":35.1258,"halted":0,"volume":25482,"hourTrading":{"tag":"盘后","latestPrice":34.72,"preClose":34.6893,"latestTime":"16:15 EDT","volume":9,"amount":312.326514,"timestamp":1789762500328,"change":0.0307,"changeRate":0.000885,"amplitude":0.000885},"delay":0,"changeRate":-0.012426763233862154,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":-0.4365,"latestTime":"09-18 16:15:34 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":885086,"amplitude":0.014246,"askPrice":47.09,"askSize":100,"bidPrice":32.86,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007406,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.72,"preClose":34.6893,"latestTime":"16:15 EDT","volume":9,"amount":312.326514,"timestamp":1789762500328,"change":0.0307,"changeRate":0.000885,"amplitude":0.000885},"volumeRatio":1.139227,"impliedVol":0.0457,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.139227,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6893,"committee":0.333333,"eps":0,"divideRate":0.007406,"volume":25482,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667635798","title":"創新藥企赴港IPO提速 小分子創新藥成主力賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635798","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635798?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 07:52","pubTimestamp":1789343542,"startTime":"0","endTime":"0","summary":"【创新药企赴港IPO提速 小分子创新药成主力赛道】8月下旬以来，征祥医药、益方生物、迪哲医药、贝达药业、维眸生物、诺令生物、普莱医药、信立泰等多家企业，密集向港交所递交上市申请，掀起新一轮本土创新药闯关港股18A板块的热潮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["159992","BK4127","REDS","LNGR","BK1161","FRHC","BK1574","IPOS","MEDX","IBBQ","KCE","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667871386","title":"華泰證券：港股基本面與貼現率賽跑 首選紅利及創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667871386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667871386?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 23:44","pubTimestamp":1789314266,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VXUS","LNGR","BK4588","KCAI","MEDX","IBBQ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667682589","title":"B7-H3靶點ADC全球率先突破 世界肺癌大會迎來中國時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2667682589","media":"中国新闻网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667682589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 20:11","pubTimestamp":1789301465,"startTime":"0","endTime":"0","summary":"9月13日，韩国首尔，世界肺癌大会(WCLC)主席论坛。中山大学肿瘤防治中心张力教授分享了B7-H3抗体偶联药物依康坦博妥塔单抗(Tam-Peli，代号YL201)对比盐酸托泊替康用于治疗复发性小细胞肺癌的Ⅲ期注册研究TAISHAN-302成果，这是全球范围内以B7-H3为靶点的ADC首次公布Ⅲ期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872861815.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872861815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","BK1161","KURE","IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667272684","title":"WCLC大會開幕！一文搞懂創新藥臨床指標","url":"https://stock-news.laohu8.com/highlight/detail?id=2667272684","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667272684?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:26","pubTimestamp":1789298760,"startTime":"0","endTime":"0","summary":"9月12日，2026年WCLC正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司公布旗下核心产品临床数据。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。文中提及个股在恒生港股通创新药精选指数中的权重占比情况见配图。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvw4447257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","IBBQ","159992","BK1574","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684274","title":"創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684274","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667684274?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:25","pubTimestamp":1789298700,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvy5397470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159316","BK1574","IBBQ","LNGR","FLHK","BK1161","159992","520880","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684278","title":"情緒冰點，A股單周成交額創年內新低！有色領跌，創新藥不振！關注華寶基金創業板人工智能ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684278","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667684278?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:24","pubTimestamp":1789298640,"startTime":"0","endTime":"0","summary":"本周，A股主要指数整体承压、多数收跌，创指逆市上涨1.08%一枝独秀，市场显著缩量，累计成交9.46万亿元，创年内单周地量，短期情绪或触冰点。资金关注高“光”指数布局机会，创业板人工智能ETF华宝场内热度高企，标的指数日内“V”型拉升。该规则已于7月22日通过，拟于9月11日在联邦公报正式刊载，30日后正式生效。三重因素扰动，有色ETF跳空下跌！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvw4446663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159967","CNXT","TECY","WPAI","CPNQ","510300","MEDX","06978","QSWN","000001.SH","QID","161631","LNGR","399300","CWC","CHAT","510880","03188","GK","KOMP","TARK","MFIG","AGIX","FWD","IBBQ","MVPS","159876","QQA","512510","VUSE","QTOC","PBOT","NEWZ","159992","000300.SH","DQJN","LCLG","399006","NBDS","AIFD","AQGX","000688.SH","OGIG","ARTY","AIBU","AIQU","159915","159982","FDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667681787","title":"從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667681787","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667681787?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 17:19","pubTimestamp":1789291195,"startTime":"0","endTime":"0","summary":"日前，上海创新药企复宏汉霖举办2026年开放日活动，围绕全球化布局、生物类似药商业化、创新研发及临床开发等话题披露最新进展。复宏汉霖执行董事、首席执行官朱俊博士介绍，截至目前，复宏汉霖已有4款产品获美国食品药品监督管理局（FDA）批准、5款获欧盟（EC）批准、8款获中国国家药品监督管理局（NMPA）批准，产品已惠及全球超过110万名患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872844911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872844911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","06978","BK1161","HK0000320264.USD","02696","IBBQ","MEDX","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","HK0000306701.USD","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457170","title":"阿斯利康：SERENA-4臨床試驗未達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457170?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:16","pubTimestamp":1789157801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","IBBJ","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666798529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","159992","IBBQ","06978","MEDX","ORR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529140","title":"重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529140","media":"新浪基金","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529140?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:17","pubTimestamp":1789125420,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhry5675751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","520880","159316","MEDX","06978","159992","IBBQ","BK1161","BK1574","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666452917","title":"放量普跌！有色突遭重挫，創新藥跌跌不休！光模塊逆市獨漲，高「光」創業板人工智能ETF（159363）V型拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666452917","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666452917?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:15","pubTimestamp":1789125300,"startTime":"0","endTime":"0","summary":"有色板块领跌全市场，揽尽有色金属行业龙头的有色ETF华宝标的指数收跌4.04%失守所有均线。FCC政策落地，光通信担忧明显缓解，光模块龙头逆市走强，中际旭创逆市收涨4%，新易盛涨近3%，高“光”创业板人工智能ETF华宝标的指数日内“V”型拉升。中际旭创、新易盛逆市上涨，高“光”指数V型拉升！*布局高“光”主线+AI应用，建议关注创业板人工智能ETF华宝及场外联接，重点布局光模块CPO龙头，兼顾AI应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrq6694331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159363","AIBU","AIQU","QQA","QTOC","MEDX","399006","LUMA","LYTE","OGIG","FWD","TARK","515890","PBOT","159992","CHAT","MFIG","AGIX","CPNQ","KOMP","AAOZ","159915","NBDS","159982","CWC","161631","MVPS","QSWN","LCLG","GK","TECY","510300","CNXT","WPAI","399300","AIFD","DQJN","06978","000001.SH","512510","AQGX","IBBQ","159876","QID","NEWZ","FDN","LNGR","VUSE","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544063","title":"興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:54","pubTimestamp":1789113276,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300573","IBBQ","MDTX","BMED","IBBJ","BK0177","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226544","title":"興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:47","pubTimestamp":1789112862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","BMED","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544925","title":"昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544925","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544925?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"9 月 6 日，昂利康发布公告宣布终止与亚飞生物、亲合力的 IMD\u001e1005肿瘤抗体药物授权许可合作。02主业盈利出现下滑，创新转型面临双重考验创新药引进受挫的同时，昂利康主业经营已经显现压力。原料药业务是昂利康的基本盘，业绩下滑说明核心主业易受行业周期、市场供需波动冲击，自身抗周期能力有待加强。未来昂利康既要稳固原料药基本盘，也需要平衡好资金投入与管线风险，审慎推进授权引进类项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5384750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","LNGR","MEDX","002940","BK1161","IBBQ","159992","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544603","title":"一品紅痛風創新藥Ⅲ期臨床達到主要終點 大中華區銷售峯值預計達19.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544603","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544603?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:34","pubTimestamp":1789112040,"startTime":"0","endTime":"0","summary":"近日，一品红自愿披露关于痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点的公告。商业化权益方面，AR882为一品红自主研发的1类创新药，在大中华区拥有完整的开发、生产与商业化权益，且一品红具备成熟的自有慢病药商业化团队，无需对外支付销售分成。结合0.70的临床成功概率，最终AR882大中华区痛风适应症管线的风险调整净现值约为5.5亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-11/doc-inirmvzz2155509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1574","BK0239","BK1161","300723","MEDX","159992","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股異動 | 創新藥概念股持續調整 海外利率預期反覆 2026國談收官進入結果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510786?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","LU1813983027.USD","LU1831875114.USD","LU0067412154.USD","LU1188198961.HKD","IE00BZ08YT58.USD","BK1191","LU0326950275.SGD","LU0501845795.SGD","BK4585","06978","LU2328871848.SGD","159992","LU2488822045.USD","BK1161","01093","IE0008369823.USD","LU2097828557.USD","LU1226288170.HKD","KCAI","LU0072913022.USD","MEDX","IE00B5MMRT66.SGD","LU1328277881.USD","LU0455707207.USD","BK1589","PEVC","LU1226287875.USD","LU0244354667.USD","IE0008368742.USD","LU1008478684.HKD","09995","BK1515","LU0149534421.HKD","LU2097828474.EUR","LU1960683339.HKD","VXUS","LU0880133367.SGD","WRTH","02157","KURE","LU2242644610.SGD","01801","LU1807302812.USD","IBBQ","LU2097828805.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU1969619763.USD","MCRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751737","title":"涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751737","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751737?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:17","pubTimestamp":1789085820,"startTime":"0","endTime":"0","summary":"停牌前，拨康视云报1.19港元，较2025年7月上市发行价10.1港元，累计蒸发约88%。这是一间成立于2015年、专注眼科创新药的临床阶段生物科技公司，四次递表才闯关成功，上市首日即告破发，如今在监管介入调查中股票停牌，前路未卜。证监会表示，调查仍在进行中，暂不作进一步评论。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-09-11/doc-inirmfea2271775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","BK4127","IPOS","KCE","IBBQ","BK1574","REDS","159992","FRHC","02592","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511370?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","LNGR","BK1161","BK1574","MEDX","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519089","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519089?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:15","pubTimestamp":1789082138,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666602598","title":"華東醫藥：創新藥HDM2005入選國家科技重大專項","url":"https://stock-news.laohu8.com/highlight/detail?id=2666602598","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666602598?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:49","pubTimestamp":1789040985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":6,"totalSize":219,"code":"91000000","status":"200"}]}}